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Although human epidermal growth factor receptor 2 (HER2)-
targeted therapies have dramatically improved the clinical out-
come of HER2-positive breast cancer patients, innate and acquired
resistance remains an important clinical challenge. New therapeu-
tic approaches and diagnostic tools for identification, stratifica-
tion, and treatment of patients at higher risk of resistance and
recurrence are therefore warranted. Here, we unveil a mechanism
controlling the oncogenic activity of HER2: heteromerization with
the cannabinoid receptor CB2R. We show that HER2 physically inter-
acts with CB2R in breast cancer cells, and that the expression of these
heteromers correlates with poor patient prognosis. The cannabinoid
Δ9-tetrahydrocannabinol (THC) disrupts HER2–CB2R complexes by se-
lectively binding to CB2R, which leads to (i) the inactivation of
HER2 through disruption of HER2–HER2 homodimers, and (ii) the
subsequent degradation of HER2 by the proteasome via the E3 ligase
c-CBL. This in turn triggers antitumor responses in vitro and in vivo.
Selective targeting of CB2R transmembrane region 5 mimicked THC
effects. Together, these findings define HER2–CB2R heteromers as
new potential targets for antitumor therapies and biomarkers with
prognostic value in HER2-positive breast cancer.
breast cancer | HER2 | cannabinoids | receptor heteromers | CB2R
Breast cancer is a very heterogeneous disease in terms ofmolecular markers, prognosis, and treatments. According to
all subclassification methods, there is a specific subtype that is
characterized by overexpression of human epidermal growth factor
receptor 2 (HER2), which represents roughly 15 to 20% of all breast
tumors (1, 2). HER2 belongs to the ERBB (HER) receptor tyrosine
kinase family, which consists of four members: HER1 (epidermal
growth factor receptor; EGFR), HER2, HER3, and HER4. HER2
promotes oncogenic signaling by modulating the expression and ac-
tivity of proteins controlling cell proliferation, differentiation, death,
migration, and angiogenesis. Activation of HER2 is achieved by li-
gand- or overexpression-induced dimerization with other members of
the family, followed by trans-phosphorylation and autophosphor-
ylation of the two constituents of the HER homo/heterodimer in
their cytosolic kinase domains (3, 4). Overexpression of HER2 in
some ways is a paradigm for the design of targeted therapies for the
management of this subtype of tumors. Thus, trastuzumab, a
recombinant humanized monoclonal anti-HER2 antibody, has sig-
nificantly improved the outcome of these patients (1, 4, 5). Despite its
efficacy in many HER2+ breast cancer cases, some patients do not
respond to this treatment and others eventually progress. Identifying
the molecular mechanisms underlying HER2 activation (i.e., di-
merization, trans- and autophosphorylation) has allowed the de-
sign of additional tools to overcome resistance to trastuzumab and
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improve the treatment of these tumors. For example, pertuzumab,
another anti-HER2 monoclonal antibody, was designed to spe-
cifically target the dimerization domain of HER2, and lapatinib,
a tyrosine kinase inhibitor, to selectively inhibit the trans- and
autophosphorylation of HER1 and HER2 (1, 4, 5). Simultaneous
targeting of HER2 at different levels (i.e., combination of the
aforementioned agents) is showing better clinical outcomes than
anti-HER2 monotherapies, but some patients still present with
either innate or acquired resistance (1, 5). Therefore, new/
complementary therapeutic approaches are urgently needed to
both identify and treat this patient population.
Cannabinoids, the active constituents of cannabis, produce
antitumor responses in preclinical models of cancer, including
HER2+ breast cancer (6–9). In most cases, the antitumor re-
sponses are produced by binding and activating cannabinoid
receptors. CB1R and CB2R, the two cannabinoid receptors de-
scribed so far, belong to the G protein-coupled receptor (GPCR)
superfamily of membrane proteins. While CB1R, the main re-
ceptor responsible for the psychoactive effects of cannabis, is
widely expressed throughout the body and especially abundant in
the central nervous system, CB2R, in healthy individuals, is
mainly restricted to elements of the immune system. However,
increasing evidence shows that the expression of this receptor is
augmented in many pathological states, including cancer (6–8).
In fact, the preclinical research conducted so far in preclinical
models of HER2+ breast cancer points to CB2R as the main
target of cannabinoid antitumor action (10, 11).
Here, we aimed at getting a deeper insight into the mecha-
nisms of HER2 activation/inactivation, to provide new potential
targets for treatment of HER2+ tumors. Specifically, we studied
the functional relevance of a recently described heteromer
between HER2 and the cannabinoid receptor CB2. We have
previously reported the presence of these complexes in HER2+
breast cancer tumors (12), but their role in HER2 function is as
yet unknown. In this context, the main goal of this study was to
determine the role of HER2–CB2R heteromers in HER2+
breast cancer pathology and, overall, whether these structures
could be new targets for anticancer treatments.
Results
HER2–CB2R Heteromer Expression Correlates with Poor Patient
Prognosis. We have previously described that CB2R promotes
HER2 prooncogenic signaling, and that these two membrane
receptors physically interact in HER2+ breast cancer cells and
tissue (12). However, the functional relevance of these hetero-
mers is completely unknown. To evaluate their role in breast
cancer, we first analyzed the expression of these complexes in a
series of 57 human HER2+ breast cancer biopsies obtained at
the time of first diagnosis, before any treatment [tissue micro-
array (TMA) 1 in Materials and Methods]. Proximity ligation
assays (PLAs) (Fig. 1A) showed that higher HER2–CB2R ex-
pression in tumors is associated with lower disease-free patient
survival (Fig. 1B), as well as with higher spread to regional lymph
nodes and Ki67 overexpression (SI Appendix, Table S1). To fur-
ther validate these observations, we performed similar analyses in
Fig. 1. HER2–CB2R heteromer expression correlates with poor patient prognosis. Proximity ligation assays were performed in tissue microarrays and patient-
derived xenografts. (Scale bars, 25 μm.) For the TMAs, samples were ranked based on HER2–CB2R heteromer expression (i.e., PLA signal), and the best cutoff
was manually selected. (A) Representative confocal microscopy images of a low– and a high–heteromer-expressing sample in TMA 1. The red dotted signal
corresponds to the heteromers, and the blue staining corresponds to cell nuclei. (B–D) Kaplan–Meier curves for disease-free survival [from samples included in
TMA 1 (n = 57) (B) or TMA 2 (n = 39) (C)] and overall patient survival [from the HER2+ samples included in TMA 2 (n = 33) (D)]. Curves were statistically
compared by the log-rank test (P < 0.05). (E and F, Upper) Representative images of HER2–CB2R heteromer expression in two pairs of PDXs, consisting of a PDX
established from the patient’s primary tumor and a sample derived from a metastasis in the same patient [in the liver in one case (E), and in a lymph node in
the other (F)]. (E and F, Lower) Quantification of HER2–CB2R heteromer expression in the PDX samples. Results are expressed as PLA ratio (number of red dots
per cell), and error bars represent SEM (n = 7 technical replicates in primary tumor samples; n = 5 in metastatic samples). HR, hazard ratio.
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an additional TMA containing 39 human high-grade HER2+
ductal breast cancer samples obtained before any treatment
(TMA 2 inMaterials and Methods). High HER2–CB2R heteromer
expression was also associated with poor patient prognosis, spe-
cifically lower disease-free and overall patient survival (Fig. 1 C
and D). Positive and negative controls for HER2–CB2R hetero-
mer expression are shown in SI Appendix, Fig. S1 A–D. The sep-
arate analysis of either HER2 or CB2R by immunohistochemistry
confirmed two issues. First is that increased heteromer expression
is not just a consequence of individual receptor overexpression.
Thus, similar HER2–CB2R heteromer levels were found in tumors
with low, medium, or high HER2 expression (SI Appendix, Fig.
S1E), as well as with no, low, medium, or high CB2R expression
(SI Appendix, Fig. S1F). Second is that HER2–CB2R heteromer
expression is a better prognostic marker than HER2 alone or
CB2R alone. Thus, no association between HER2 expression and
disease-free survival was found in TMA 1 (SI Appendix, Fig. S2A);
for CB2R expression, although there seemed to be an association
trend with disease-free survival, it did not reach statistical signif-
icance either (SI Appendix, Fig. S2B). In addition, we analyzed
heteromer expression in two pairs of patient-derived xenografts
(PDXs). Each pair consisted of one PDX generated from the
patient’s primary tumor and another PDX generated from
the corresponding metastasis (in the liver in one case, and in a
lymph node in the other). Consistent with the idea that HER2–
CB2R complexes correlate with poor patient prognosis, in both
cases we observed significantly higher heteromer expression in the
metastatic tissue with respect to the corresponding primary tumor
(Fig. 1 E and F). Together, these results show that HER2–CB2R
heteromers are specific receptor complexes present in HER2+
breast cancer tissue, and are associated with tumor recurrence
and spreading.
Δ9-Tetrahydrocannabinol Disrupts HER2–CB2R Complexes and Impairs
HER2+ Breast Cancer Cell Viability. Since HER2–CB2R heteromer
expression seems to be linked to prooncogenic processes (12)
(Fig. 1), we next studied whether these complexes could be
targets for antitumor therapies. It has been previously described
that CB2R activation in different models of HER2+ breast
cancer leads to cancer cell death by apoptosis and inhibition of
tumor growth, angiogenesis, and metastasis (10, 11). To determine
if HER2–CB2R heteromers are involved in this cannabinoid an-
titumor action, we analyzed their expression in response to Δ9-
tetrahydrocannabinol (THC; the main bioactive constituent of
cannabis). We first used HEK293 cells transiently transfected with
HER2 and CB2R as a model. In this system, we confirmed the
formation of HER2–CB2R complexes by bioluminescence reso-
nance energy transfer (BRET) (Fig. 2 A and B). The heteromer
signal significantly decreased upon THC treatment (Fig. 2C). The
cannabinoid-induced decrease in both HER2–CB2R and cell vi-
ability relied on CB2R activation, as indicated by the preventive
effect of the CB2R-selective antagonist SR144528 (SR2; Fig. 2 C
and E). In addition, and supporting the idea that HER2–CB2R
heteromers are unique signaling structures, we observed that upon
exposure to THC, CB2R coupling shifts to a different set of het-
erotrimeric G proteins. Thus, in cells only expressing CB2R, THC
induced the coupling of the receptor to Gq/11, while it promoted
the coupling to Gi and Gz when HER2 and CB2R were coex-
pressed (SI Appendix, Fig. S3).
To determine whether the effects observed in HEK293 cells
also occur in more physiological settings, we ran a series of ex-
periments in two different human HER2+ breast cancer cell
lines (BT474 and HCC1954). THC decreased the viability of
both cell lines in a concentration-dependent manner (Fig. 2F),
an effect that was again prevented by SR2 (Fig. 2G). The in-
teraction between HER2 and CB2R in these cells was then an-
alyzed by coimmunoprecipitation upon overexpression of an
HA-tagged form of CB2R. THC treatment diminished the
amount of CB2R that coimmunoprecipitated with HER2 in both
cell lines, which points to a cannabinoid-induced disruption of
the heteromer (Fig. 2H). The decrease in HER2–CB2R com-
plexes was not due to a reduction in the receptors’ expression, as
they remained unchanged after a 4-h THC treatment (Fig. 2H).
To further support the idea that THC disrupts HER2–CB2R
heteromers, we performed PLAs in the two breast cancer cell
lines in native conditions (i.e., under no overexpression of
HER2 or CB2R). Data showed that THC decreases the amount
of these complexes by activating CB2R (Fig. 2 I and J).
HER2–CB2R Heteromer Disruption by THC Hampers HER2 Activation.
HER2 activation occurs upon dimerization with other members
of the HER family, followed by trans- and autophosphorylation of
the intracellular domains of each protomer (13). We analyzed
whether disruption of the HER2–CB2R heteromer by THC had any
effect on this activation process. First, and to determine which
specific HER dimers may be affected by HER2–CB2R disruption,
we evaluated the expression of the four members of the HER family
in the two HER2+ cell lines used in our studies. In addition to
HER2, we found HER1 and HER3 overexpression in at least one of
them compared with a luminal (MCF7) or a basal (MDA-MB-231)
breast cancer cell line (Fig. 3A). We therefore studied the effect of
THC on HER2–HER1, HER2–HER2, and HER2–HER3 het-
eromers in HCC1954 cells. Neither HER2–HER1 nor HER2–
HER3 complexes were affected by cannabinoid treatment (Fig. 3 B
and C). In contrast, THC significantly diminished the amount of
HER2–HER2 homodimers (Fig. 3 B and C), and this effect was
prevented by SR2 (Fig. 3 D and E). HER2–HER2 homodimer
reduction upon THC challenge, and involvement of CB2R in this
effect, were further confirmed by BRET in HEK293 HER2–CB2R
cells (Fig. 3F). As expected, THC produced no such action in
HEK293 cells lacking CB2 receptors (Fig. 3G). In line with these
observations, THC decreased the levels of HER2 phosphorylated at
Tyr1248 (Fig. 3 H and I), one of the main autophosphorylation sites
in this receptor. Taken together, these observations demonstrate
that HER2–CB2R heteromer disruption by THC hampers HER2
activation by interfering with its homodimerization.
THC Induces HER2–CB2R Heteromer Disruption and HER2 Degradation
in Vitro and in Vivo. Cannabinoid challenge produced a marked
decrease in the levels of activated (phospho-Tyr1248) HER2
(Figs. 3 H and I and 4 A and B), that was followed by a decrease
in the total levels of HER2 (Fig. 4 A and B). This effect was
prevented by blockade of CB2R (Fig. 4C), and was not due to
inhibition of gene transcription, as indicated by the observation
that HER2 mRNA levels remained unchanged (Fig. 4D). These
results suggest that THC produces both an impairment of
HER2 prooncogenic activity and the triggering of antitumoral
signaling through CB2R activation. In line with this notion, in-
activation of both ERK and AKT was observed 24 h after THC
treatment, and this was prevented by CB2R pharmacological
blockade as well as by HER2 knockdown, which reduced pERK
and pAKT per se (SI Appendix, Fig. S4).
Importantly, THC also produced the disruption of HER2–
CB2R heteromers in vivo, an effect that was associated with
HER2 degradation and antitumor responses. Thus, THC sig-
nificantly decreased the growth of orthotopic xenografts gener-
ated in immunodeficient mice by injection of HCC1954 cells
(Fig. 4E), and tumors from the THC-treated group showed sig-
nificantly reduced HER2 protein levels (Fig. 4 F and G) as well
as significantly reduced HER2–CB2R and HER2–HER2 PLA
signal (Fig. 4 H and I), compared with vehicle-treated animals.
One of the main mechanisms of intracellular protein degra-
dation is proteolytic hydrolysis by the proteasome (14). Blockade
of the proteasome system with lactacystin prevented the decrease
of HER2 levels induced by THC in BT474 breast cancer cells
(Fig. 5 A and B). We performed similar experiments in HCC1954
cells, but they showed hypersensitivity to proteasome inhibition
and died in response to low concentrations of lactacystin. THC
also increased the levels of ubiquitinated HER2 (Fig. 5C). The
main E3 ligases reported so far to be responsible for HER2
degradation are CHIP and c-CBL (15). While cannabinoid
treatment did not modify the levels of the former, it significantly
Blasco-Benito et al. PNAS | February 26, 2019 | vol. 116 | no. 9 | 3865
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increased the amount of c-CBL in BT474 and HCC1954 cells (Fig.
5 D and E). Moreover, THC augmented the extent of HER2
phosphorylation at Tyr1112, the residue that is specifically rec-
ognized by c-CBL and triggers HER2 polyubiquitination (16) (Fig.
5F). Involvement of c-CBL in HER2 degradation was further
supported by genetic blockade. siRNA-driven targeting of this
E3 ligase prevented THC-induced decrease of total HER2 levels
in the two breast cancer cell lines tested (Fig. 5 G and H).
Collectively, these findings demonstrate that THC disrupts
HER2–CB2R heteromers, blocks HER2 activation, and pro-
motes its degradation through the proteasome system via c-CBL
activation, which results in antitumor responses.
HER2–CB2R Heteromer Disruption by Targeting CB2R Transmembrane
5 Mimics THC Effects. To determine whether the effects described
above were THC-specific or could also be produced by other
tools that disrupt HER2–CB2R heteromers, we used two dif-
ferent experimental approaches aimed at blocking the physical
interaction between HER2 and CB2R. First, and to determine
which part of the cannabinoid receptor is involved in the in-
teraction with HER2, we generated a series of truncated proteins
containing the N-terminal domain of CB2R, followed by one of
the seven transmembrane (TM) domains of the receptor and its
C-terminal domain. All constructs contained an HA tag in the N-
terminal domain (Fig. 6A). Coimmunoprecipitation assays in
HEK293 cells cotransfected with HER2 and the different CB2R
constructs showed a potential interaction between HER2 and
TMs 1, 3, 4, and 5 of CB2R (Fig. 6B). To determine which of
them was more plausible to participate in the physical interaction
between the two receptors, we performed bimolecular fluores-
cence complementation (BiFC) assays in HEK293 cells (Fig.
6C). A fluorescent, proximity-evoked signal was observed when
the HER2 fusion protein was cotransfected with the CB2R fu-
sion protein and the constructs containing CB2R TMs 1, 2, 3, 6,
and 7 (Fig. 6D). This signal was significantly reduced upon
cotransfection with CB2R TMs 4 and 5 (Fig. 6D), which is in-
dicative of heteromer disruption. Since TM5 has been previously
described to be involved in interactions between GPCRs (17–
19), we focused our studies on this specific transmembrane do-
main. A TM5-targeted peptide (CB2R TAT-TM5) was then used
to prevent the association between CB2R and HER2. The use of
this type of peptide has been widely reported in the literature,
and it is broadly accepted as a tool for disrupting GPCR–GPCR
interaction (20, 21). BiFC experiments confirmed that this tool
selectively blocks the formation of HER2–CB2R heteromers
(Fig. 6E). Thus, the fluorescent signal indicative of the presence
of HER2–CB2R heteromers disappeared when cells were in-
cubated with the CB2R TAT-TM5 peptide, and not when they
were challenged with a D44R TAT-TM5–targeted peptide (used
as negative control) (Fig. 6E). Similar data were obtained when
PLAs were carried out in native untransfected HER2+ breast
cancer cells (Fig. 7A), that is, a significant decrease in the dotted
fluorescent signal corresponding to the heteromers appeared
upon CB2R TAT-TM5 treatment, which was not evident when
the D44R TM5 peptide was used (Fig. 7 A and B). Of interest,
and as observed for THC, disruption of HER2–CB2R heteromers
by the CB2R TAT-TM5 peptide produced (i) HER2 inactivation,
as demonstrated by a dramatic decrease in the formation of
HER2–HER2 homodimers (Fig. 7 C and D) and in the levels of
phosphorylated HER2 (Fig. 7 E and F); (ii) HER2 degradation,
evidenced by a marked reduction in total HER2 protein levels
(Fig. 7 E and F); and (iii) a concomitant decrease in the viability
of HER2+ breast cancer cells (Fig. 7G) that was not observed in
wild-type HEK293 cells, which do not express either HER2 or
CB2R (Fig. 7G). Altogether, these results show that disruption of
HER2–CB2R heteromers, either with THC or with other tools
aimed at interfering with the physical interaction between CB2R
TM5 and the transmembrane domain of HER2, dramatically
impairs the viability of HER2+ breast cancer cells.
Fig. 2. THC decreases HER2–CB2R complexes. (A) Schematic representation of bioluminescence resonance energy transfer experiments. (B) BRET saturation
curve in HEK293 cells transfected with a fixed concentration of HER2-Rluc and increasing concentrations of CB2R-YFP. HER2-Rluc/GHS-R1a-YFP and D44R-Rluc/
YFP were used as negative controls for the interaction (n = 8). (C) Effect of THC (4 h), alone or in combination with the CB2R-selective antagonist SR144528
(SR2; 1 μM), on HER2-Rluc/CB2R-YFP BRETmax signal in HEK293 cells (n = 3). (D and E) Viability of CB2R- and HER2-transfected HEK293 cells after 24-h treatment
with increasing concentrations of THC (n = 5) (D), or THC in combination with SR2 (1 μM) (n = 4) (E). (F and G) Viability of BT474 (n = 6) and HCC1954 (n = 3)
cells in response to increasing concentrations of THC (F), or in combination with the CB2R-selective antagonist SR144528 (1 μM) (G). Results (n = 3 to 6 in-
dependent experiments) are expressed as percent vs. vehicle-treated cells, set at 100%, and error bars represent SEM. (H) Coimmunoprecipitation of
HER2 with CB2R after THC treatment (4 h), in BT474 and HCC1954 cells transfected with an HA-tagged CB2R plasmid. IP, immunoprecipitation. (I) Repre-
sentative PLA confocal microscopy images of HER2–CB2R heteromers (in red) in BT474 (Upper) and HCC1954 cells (Lower), treated with THC (4 h) alone or in
combination with SR2 (1 μM). Cell nuclei are stained in blue. (Scale bars, 25 μm.) (J) Quantification of HER2–CB2R PLA signal (number of red dots per cell) (n =
3). Results are expressed as percent vs. vehicle-treated cells, set at 100%, and error bars represent SEM. Multigroup comparisons were analyzed by one-way
ANOVA with Tukey’s post hoc test. *P < 0.05, **P < 0.01 vs. vehicle-treated cells; #P < 0.05, ##P < 0.01 vs. THC.
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Discussion
Here, we describe a mechanism controlling the activity of HER2
that may constitute a new target for antitumor treatments. Spe-
cifically, we observed that HER2 physically interacts with a
membrane receptor that does not belong to the HER family
(cannabinoid receptor CB2R), thus forming HER2–CB2R het-
eromers, and that disrupting these complexes triggers the inacti-
vation and degradation of HER2, promoting in turn antitumoral
responses. The HER2–CB2R heteromers described herein fulfill
the three criteria required for demonstrating receptor hetero-
merization (20, 21): First, the heteromer component (HER2 and
CB2R) interaction is demonstrated by proximity-based techniques
and coimmunoprecipitation; second, HER2–CB2R heteromers
exhibit properties distinct from those of the protomers, as dem-
onstrated by the coupling of CB2R to different heterotrimeric G
proteins depending on whether it is part of the heteromer or not;
and third, heteromer disruption leads to a loss of heteromer-specific
properties, as demonstrated by the fact that while HER2–CB2R
complexes are linked to prooncogenic events (12), disruption of the
heteromers leads to antitumor responses.
Interaction of HER2 with other membrane receptor tyrosine
kinases (RTKs) is a common and well-described process. Di-
merization with other members of the HER family, for example,
is a necessary step for HER activation, and in fact some drugs
have been already designed to interfere with this step and block
the subsequent prooncogenic signaling (4). An increasing num-
ber of studies demonstrate that GPCRs also interact physically
between them, generating unique signaling platforms (GPCR
heteromers) with physiopathological implications different from
those of the constituting monomers. Most have been described in
the central nervous system, and are becoming potential thera-
peutic targets for disorders such us addiction, pain, Parkinson’s
disease, and schizophrenia (21–23). Heteromers between cyto-
kine and adrenergic receptors have also been described, with
implications in blood pressure regulation (21, 23), or between
different GPCRs in distinct endocrine systems, which may con-
stitute new targets for endocrine-related disorders (24). Canna-
binoid receptors in particular have been long described as
constituents of particular GPCR receptor heteromers. Thus,
CB1R physically interacts with CB2R (25), serotonin (26), aden-
osine (22, 27), opioid (28), orexin (29), and angiotensin (30) re-
ceptors, and with the cannabinoid-related orphan receptor GPR55
(31). CB2R, on the other hand, has been shown to form hetero-
mers with GPR55 (32, 33) and CXCR4 (34, 35). Although sev-
eral RTK–RTK heteromers and GPCR–GPCR heteromers have
been previously described, there are very few examples of phys-
ical interaction between RTKs and GPCRs yet. Transactivation
of RTKs by GPCRs and vice versa has been reported and in some
cases physical interactions have been suggested, but no solid proof
of the existence of such heteromers has been provided in most
cases (36). Usually, colocalization, coimmunoprecipitation, and
pharmacological transmodulation of the protomers in nonnative
cell systems are the only evidence suggesting the presence of the
heteromer, but this is clearly insufficient. Colocalization does not
provide enough subcellular resolution to establish close prox-
imity, and even coimmunoprecipitation can occur with receptors
too far apart to directly modulate one another. Transactivation is
no doubt a very interesting pharmacological process, but dem-
onstrating the existence of receptor heteromers has additional
importance in terms of providing new druggable therapeutic
targets. To the best of our knowledge, the best-characterized
RTK–GPCR heteromer is that formed by HER2 and β2-adrenergic
Fig. 3. HER2–CB2R heteromer disruption by THC
hampers HER2 activation. (A) HER1, HER2, HER3, and
HER4 expression, as determined by Western blot
analysis, in the indicated breast cancer cell lines. (B)
Representative PLA confocal microscopy images of
the effect of THC (4 h) on HER2–HER1 (n = 4), HER2–
HER2 (n = 5), and HER2–HER3 (n = 3) dimers (in red)
in HCC1954 cells (B), with the corresponding quan-
tification (C), or on HER2–HER2 expression after THC
treatment, alone or in combination with the CB2R-
selective antagonist SR144528 (1 μM) (n = 3) (D), with
the corresponding quantification (E). Cell nuclei are
in blue. (Scale bars, 20 μm.) (F and G, Left) Schematic
representation of the BRET experiments conducted
in HEK293 cells. CoH, coelenterazine H. (F and G,
Right) Quantification of HER2-Rluc/HER2-YFP BRETmax
after THC treatment (4 h) alone or in combina-
tion with SR2 (1 μM) where indicated, in cells
cotransfected with HER2-Rluc, HER2-YFP, and a CB2R
untagged receptor (n = 3) (F), or an empty vector
(n = 4) (G) (used as a negative control for THC acti-
vation). In C and E–G, results are expressed as per-
cent vs. vehicle-treated cells, set as 100%, and graph
bars represent SEM. (H) Expression of pHER21248 in
BT474 and HCC1954 cells, as determined by Western
blot, upon THC treatment at the indicated times. (I)
Quantification. Results are normalized vs. the cor-
responding total HER2 levels at each individual time
point, and expressed as fold increase vs. time 0, set at
1 (n = 4 in BT474; n = 7 in HCC1954). Error bars
represent SEM. Unpaired independent groups of
two were analyzed by two-tailed Student’s t test.
When multigroup comparison was required, data
were analyzed by one-way ANOVA with Tukey’s post
hoc test. *P < 0.05, **P < 0.01 vs. vehicle-treated
cells; ##P < 0.01 vs. THC. n.s., not significant.
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receptors in the heart, which seems to be essential for cardiac
homeostasis (37); by fibroblast growth factor receptor and adeno-
sine A2A receptors (38) or serotonin 5-HT1A receptors (39), which
play important roles in synaptic plasticity; and by EGFR and
GPR54, which seem to promote breast cancer cell invasiveness
(40). Here, we comprehensively describe the existence of hetero-
mers between HER2 and CB2R and provide compelling evidence
showing that their disruption promotes antitumoral responses
both in vitro and in vivo, which may constitute a new strategy to
treat HER2+ breast tumors. It is tempting to speculate that other
HER2-overexpressing tumors such as gastric or gastroesophageal
adenocarcinomas (41) may express similar CB2R–HER2 hetero-
mers, and therefore respond in a similar way to treatments aimed
at breaking up these complexes.
Our previous work had shown that, in the absence of exoge-
nously applied cannabinoids, CB2R plays a protumoral role in
HER2+ contexts (12). In line with that study, here we report that
heteromer expression correlates with poor patient prognosis. On
the other hand, there is solid evidence that pharmacological
activation of CB2R produces antitumoral responses in HER2+
preclinical settings (10, 11). Considering all these observations,
we propose the following model for HER2–CB2R function in
breast cancer (Fig. 8). Under no pharmacological treatment,
HER2+ breast cancer cells express high levels of HER2, which
up-regulate the expression of CB2R via the mechanisms de-
scribed in ref. 12. HER2 and CB2R then form heteromers in the
plasma membrane, thereby protecting HER2 from degradation
and favoring its canonical oncogenic signaling, resulting in pro-
tumoral responses (Fig. 8A). When cells are exposed to THC (or
to other tools that prevent HER2–CB2R interaction), the two
receptors physically separate. In addition, HER2–CB2R disrup-
tion triggers inactivation of HER2 (by breaking HER2–HER2
homodimers) and increases its susceptibility to degradation. As a
final consequence of HER2 degradation and CB2R activation,
an antitumor response is produced (Fig. 8B). It is also conceiv-
able that in cellular contexts of very high HER2 expression, the
role of CB2R in HER2 signaling may be less relevant than in
those with just high HER2 levels. The experiments we have
conducted clearly show a direct impact of THC on the viability of
cancer cells in culture and also in vivo. However, we cannot rule
out the involvement of other cell types in the full antitumor re-
sponse induced by THC. For example, immune cells and endo-
thelial cells express CB2R as well, and it is reasonable to
speculate that they may be affected by THC. In fact, it has been
previously demonstrated, for example, that THC impairs tumor
angiogenesis by blocking endothelial cell migration and blood
vessel formation and elongation (reviewed in ref. 42). Of note,
antitumor responses upon CB2R activation have also been de-
scribed in non-HER2+ contexts. It would be interesting to an-
alyze whether in those situations CB2R acts as a monomer in the
plasma membrane or if it forms heteromers with other RTKs like
HER1 (EGFR), which is overexpressed in many different types
of tumors (41). In favor of the latter, Elbaz et al. (43) recently
reported that CB2R impairs oncogenic EGF/EGFR signaling in
ER+ breast cancer cells. Although not proved, the authors
suggested that EGFR and CB2R may be forming complexes, and
that CB2R activation might disrupt them (43). In addition, and
similar to what we observed here, pharmacological activation of
CB1R induced the death of prostate cancer cells in culture, an
effect that was accompanied by a significant down-regulation of
EGFR (44), and coexpression of EGFR with CB1R was associ-
ated with poor patient prognosis in this type of cancer (45).
These observations demonstrate a functional interaction be-
tween another cannabinoid receptor (CB1R) and another
member of the HER family (HER1) that could be due to a mere
transactivation process or to a physical interaction similar to that
described here between CB2R and HER2.
In summary, our findings unveil a mechanism of regulation of
HER2 activity, and support HER2–CB2R heteromers as new
therapeutic targets for the management of HER2+ breast can-
cer. Although THC efficiently achieves heteromer disruption,
our data set the basis for the design of new antitumor drugs
aimed at breaking this interaction. In addition, it would be in-
teresting to design an alternative method to detect and quantify
these heteromers in human samples. Thus, anti–HER2–CB2R
antibodies or similar tools would allow not only corroboration of
the prognostic value described herein but also an easy transfer of
this knowledge to clinical practice.
Fig. 4. HER2–CB2R heteromer disruption by THC induces HER2 degradation in vitro and in vivo. (A, B, and D) Effect of THC on HER2 protein (A and B) and
mRNA levels (D) at the indicated times, as determined by Western blot and qPCR, respectively, in BT474 and HCC1954 cells. For quantification,
HER2 expression was normalized with the loading control [β-actin in B; β-actin and β-glucuronidase in D], and results (n = 4 in B; n = 3 in D) are expressed as
fold increase vs. time 0, set at 1. Data were analyzed by one-way ANOVA. (C) Western blot analysis of the effect of the CB2R-selective antagonist SR144528
(1 μM) on THC-induced HER2 protein decrease (n = 4 in BT474; n = 7 in HCC1954). (E) Growth of orthotopic tumors generated in NOD-SCID mice by injection of
HCC1954 cells into the mammary fat pad. Animals were treated with vehicle (sesame oil) (n = 10) or THC (1.5 mg per dose) (n = 9) thrice a week. Results were
analyzed by two-way ANOVA. (F) Representative Western blot of HER2 in the animal tumor samples. (G) Corresponding quantification. (H) Representative
PLA confocal microscopy images of HER2–CB2R and HER2–HER2 heteromers (red signal). Cell nuclei are in blue. (Scale bar, 50 μm.) (I) Quantification. Error bars
in B, D, E, and I represent SEM. Unpaired, two-tailed Student’s t test. *P < 0.05, **P < 0.01 vs. time 0 (B) or vehicle-treated animals in E, G, and I.
3868 | www.pnas.org/cgi/doi/10.1073/pnas.1815034116 Blasco-Benito et al.
Materials and Methods
Cell-Viability Assays. Cells were seeded at a density of 5,000/cm2 in 10% FBS-
containing medium. Twenty-four hours later, they were serum-starved
overnight and then treated with THC for 24 h. Cells were then fixed and
stained with a crystal violet solution (0.1% crystal violet, 20% methanol in
H2O) for 20 min. After intensive washing with water, the stained cells were
solubilized in methanol and absorbance was measured at 570 nm.
Cell Cultures and Transfections. Human breast adenocarcinoma cell lines
HCC1954 (CRL-2338), BT474 (HTB-20), MCF7 (HTB-22), and MDA-MB-231
(HTB-26) and the human embryonic kidney cell line HEK293T (CRL-1573)
were purchased from American Type Culture Collection. They were all au-
thenticated by short tandem repeat profiling (Genomics Core Facility at “Alberto
Sols” Biomedical Research Institute) and routinely tested for mycoplasma
contamination. Cells were cultured in RPMI (HCC1954, BT474), MEM (MCF7), or
DMEM (MDA-MB-231, HEK293T) supplemented with 10% FBS and 1% peni-
cillin/streptomycin, and BT474 and MCF7 cells with 10 μg/mL insulin as well.
They were all maintained at 37 °C in an atmosphere of 5% CO2.
For cell-culture experiments, THC (THC Pharm) was dissolved in DMSO.
Unless otherwise indicated, the concentration used was 3 μM for HCC1954
cells and 4 μM for BT474 and HEK293T cells. The CB2R-selective antagonist
SR144528 (SR2) (Tocris Bioscience) and lactacystin (Calbiochem) were dis-
solved in DMSO and added to the cell cultures (1 μM) 1 h prior to THC.
Expression vectors were transiently transfected with FuGENE HD trans-
fection reagent (Promega) in human breast cancer cells, and polyethylenimine
(PEI) (Sigma-Aldrich) in HEK293T cells. Transient genetic knockdown was done
by selective siRNA transfection with DharmaFECT 1 transfection reagent
(Dharmacon). Selective siRNAs to knock down human c-CBL were purchased
from Dharmacon as a SMARTpool. These reagents combine four SMART
selection-designed siRNAs into a single pool, which guarantees an efficiency
of silencing of at least 75%. Sequences were 5′-AAUCAACUCUGAACGAAA-3′,
5′-GACAAUCCUCACAAUAAA-3′, 5′-UAGCCCACCUUAUAUCUUA-3′, and 5′-
GGAGACAUUUCGGAUUA-3′. The control (nontargeted) siRNA was pur-
chased from Thermo Fisher Scientific.
Western Blot Analysis. Cells and tumors were lysed in RIPA buffer supple-
mented with 1 mM sodium orthovanadate, 1 mM PMSF, 2 μg/μL aprotinin,
and 2 μg/μL leupeptin (Sigma-Aldrich). Total lysates were resolved by SDS/
PAGE and electrophoretically transferred to PVDF membranes. After
blocking with 5% (wt/vol) nonfat dry milk in TBS-Tween, membranes were
incubated with the following antibodies overnight at 4 °C: rabbit polyclonal
anti-HER2 (C-18; Santa Cruz Biotechnology); mouse monoclonal anti-HER2
(44E7) and rabbit polyclonal anti–phospho-HER2 (Tyr1248) (2247) (Cell Sig-
naling Technology); rabbit polyclonal anti-HER1 (06-847; EMD Millipore);
rabbit polyclonal anti-HER3 (1B2E, 4754; Cell Signaling Technology); rabbit
polyclonal anti-HER4 (C-18; Santa Cruz Biotechnology); rabbit polyclonal
anti-HA tag (C29F4; Cell Signaling Technology); mouse monoclonal anti–
β-actin (AC-74; Sigma-Aldrich); mouse monoclonal anti–c-CBL (clone 17; BD
Biosciences); mouse monoclonal anti-STUB1 (CHIP) (ab2917; Abcam); and
mouse monoclonal anti-ubiquitin (P4D1; Santa Cruz Biotechnology). Sec-
ondary antibodies were chosen according to the species of origin of the
primary antibodies, and detected by an enhanced chemiluminescence sys-
tem (Bio-Rad). β-Actin was used as loading control. Densitometric analysis of
the relative expression of the protein of interest vs. the corresponding
control (β-actin or total HER2) was performed with ImageJ software (NIH).
Coimmunoprecipitation Assays. HCC1954 and BT474 cells were transiently
transfected with pcDNA3.1-HA-hCB2R (UMR cDNA Resource Center, Uni-
versity of Missouri, Rolla) or the corresponding empty vector (pcDNA3)
(Invitrogen) with FuGENE HD transfection reagent (Promega). HEK293 cells
were transiently cotransfected with pcDNA3-HER2, pcDNA3.1-HA-hCB2R, or
pcDNA3 containing the different CB2R transmembrane constructs (see be-
low) using PEI (Sigma-Aldrich). Forty-eight hours after transfection, cells
were lysed in a buffer containing 40 mM Hepes (pH 7.5), 120 mM NaCl, 1 mM
EDTA, 10 mM sodium pyrophosphate, 10 mM sodium glycerophosphate,
50 mM sodium fluoride, 0.5 mM sodium orthovanadate, and 0.3% CHAPS
and supplemented with 1 mM benzamidine and 0.1 mM PMSF. Cell lysates
(1 mg) were incubated with anti-HER2 antibody (C-18; Santa Cruz Bio-
technology) covalently coupled to protein G-Sepharose (GE Healthcare)
overnight at 4 °C on a rotating wheel. Immunoprecipitates were washed
with lysis buffer and Hepes buffer (25 mM Hepes, pH 7.5, 50 mM KCl),
resuspended in sample buffer, and filtered through a 0.22-μm pore size Spin-X
filter (Sigma-Aldrich). 2-Mercaptoethanol was then added to a concentration
of 1% (vol/vol), and samples were resolved by SDS/PAGE and transferred
Fig. 5. HER2–CB2R heteromer disruption by THC induces HER2 degradation via the c-CBL E3 ligase. Western blot-based analyses of the effect of different
pharmacological and genetic tools on THC-induced HER2 degradation. (A and B) Effect of lactacystin (LAC; 1 μM) on BT474 cells (n = 4). (C–F) Effect of THC
(4 h) on ubiquitinated HER2 (UB) (C), on c-CBL and CHIP levels (D and E), or on HER2 phosphorylation at Tyr1112 (F) in the indicated breast cancer cell lines. (G
and H) HER2 protein expression after genetic silencing of c-CBL with selective siRNAs (siCBL). A nontargeted siRNA was used as a control (siC). The densi-
tometric analyses of HER2 immunoblots were normalized to β-actin (n = 4 in B; n = 6 in E; n = 4 in H). Results are expressed as fold increase vs. vehicle-treated
cells, set at 1, and graph bars represent SEM. Unpaired, independent groups of two were analyzed by two-tailed Student’s t test. When multigroup com-
parison was required, data were analyzed by one-way ANOVA with Tukey’s post hoc test. *P < 0.05, **P < 0.01 vs. vehicle-treated group; #P < 0.05, ##P <
0.01 vs. THC-treated group.
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to PVDF membranes. Membranes were blotted with anti-HA antibody (Cell
Signaling Technology).
Ubiquitination Assays. Cells were lysed after 4 h of THC or DMSO treatment
using RIPA buffer supplemented with 1 mM sodium orthovanadate, 0.1 mM
PMSF, and 20 mM N-ethylmaleimide. Cell lysates (1 mg) were immunopre-
cipitated with an anti-HER2 antibody (C-18; Santa Cruz Biotechnology) or
preimmune IgG overnight at 4 °C on a rotating wheel. Cell lysates were then
incubated with protein G-Sepharose and then washed in RIPA lysis buffer.
Finally, immunoprecipitates were resuspended in sample buffer containing 2-
mercaptoethanol. Samples were then resolved and electrophoretically trans-
ferred to PVDF membranes and blotted with mouse monoclonal anti-ubiquitin
antibody (P4D1; Santa Cruz Biotechnology).
Real-Time Quantitative PCR. RNA was isolated with TRIzol reagent (Invi-
trogen), and cDNA was obtained with Transcriptor Reverse Transcriptase
(Roche Applied Science). Real-time quantitative PCR assays were performed
using FastStart Master Mix with Rox (Roche). The primers used for ERBB2
(HER2) were as follows: forward, 5′-GGGAAACCTGGAACTCACCT-3′; reverse,
5′-CCCTGCACCTCCTGGATA-3′. Each value was adjusted by using β-actin
(forward, 5′-CCAACCGCGAGAAGATGA-3′; reverse, 5′-CCAGAGGCGTA-
CAGGGATAG-3′) and β-glucuronidase (forward, 5′-CGCCCTGCCTATCTG-
TATTC-3′; reverse, 5′-TCCCCACAGGGAGTGTGTAG-3′) levels as references.
Immunohistochemistry. Tissue sections were subjected to a heat-induced anti-
gen retrieval step before exposure to a rabbit polyclonal anti-CB2R (101550;
Cayman Chemical) or a rabbit anti-HER2 primary antibody (HercepTest;
DAKO). Immunodetection was performed using the Envision method with
diaminobenzidine as the chromogen (DAKO). To quantify CB2R expression
in the TMA, cases were scored as 0 (no staining), 1 (weak staining), 2
(moderate staining), or 3 (high staining). HER2 staining was scored in
accordance with the HercepTest manufacturer’s guidelines.
In Situ Proximity Ligation Assays. For PLAs in the TMA and in sections of the
patient-derived xenografts, samples were deparaffinized and submitted to
heat-induced antigen retrieval in sodium citrate buffer (10 mM sodium cit-
rate, 0.05% Tween 20, pH 6.0). TMA-, PDX-, and xenograft-derived slices were
permeabilized with PBS containing 0.01% Triton X-100. For PLAs in cell
cultures, cells were seeded on glass coverslips at 5,000/cm2. After overnight
serum starvation, cells were treated for 4 h with THC, TAT-TM peptides
(4 μM), or the corresponding vehicle. They were then fixed in 4% para-
formaldehyde and permeabilized with 0.05% Triton X-100.
Heteromers were detected by using the Duolink In Situ PLA Detection Kit
(Sigma-Aldrich) following the manufacturer’s instructions. For detection of
HER2–CB2R heteromers, cells were incubated with equal amounts of a rabbit
Fig. 6. CB2R transmembrane domain 5 is involved in HER2–CB2R hetero-
dimerization. (A) Schematic representation of the HA-tagged truncated
forms of CB2R used in this study. Each construct contains the HA tag, fol-
lowed by the N-terminal domain of the receptor, one of its seven trans-
membrane domains, and the C-terminal end. (B) Each of the seven CB2R
constructs (named HA-TMX, where X is the corresponding transmembrane
domain) and a pcDNA3-HER2 plasmid was coexpressed in HEK293 cells. Im-
munoprecipitation of HER2 with an anti-HER2 antibody was followed by
Western blot analysis with an anti-HA antibody. Full-length pcDNA3-HA-
CB2R was also coexpressed with HER2 as a positive control of interaction. (C)
Schematic representation of the bimolecular fluorescence complementation
experiments between HER2-cYFP and CB2R-nYFP in the absence (Upper) or
presence of the CB2R transmembrane constructs (Lower). (D and E) Com-
plementation signal (i.e., fluorescence at 530 nm) of HEK293 cells trans-
fected with CB2R-cYFP, HER2-nYFP, and the indicated CB2R TM constructs
(n = 3) (D), or after 4 h of incubation with the indicated TAT-TM peptides
(4 μM) (n = 3) (E). Results were analyzed by one-way ANOVA with Tukey’s
post hoc test. Error bars represent SEM. **P < 0.01 vs. pcDNA3 (D) or vehicle-
treated group (E).
Fig. 7. HER2–CB2R heteromer disruption by targeting CB2R TM5 mimics THC
effects. (A–D) Effect of TM peptides on HER2–CB2R and HER2–HER2 heteromer
expression as determined by PLA. (A and C) Representative PLA images in the
indicated breast cancer cell lines, after treatment for 4 h with vehicle (DMSO), a
TAT-TM peptide targeting CB2R TM5 (4 μM), or a TAT-TM peptide targeting
dopamine receptor D44 TM5 (4 μM), used as a negative control. Dimer signal is
in red, and cell nuclei are in blue. (Scale bars, 25 μm.) (B and D) Results (n =
7 technical replicates) are expressed as percent of PLA (red dots per cell) vs.
vehicle-treated cells, set as 100%. (E ) pHER21248 and HER2 protein levels, as
determined by Western blot, after treatment with vehicle, CB2R TAT-TM5,
or D44R TAT-TM5 peptides for 24 h in BT474 and HCC1954 cells. (F ) Den-
sitometric analysis of HER2 normalized to β-actin (n = 3). Results are rep-
resented as fold increase vs. vehicle-treated cells, set as 1. (G) Viability of
HCC1954, BT474, and HEK293 cells in response to the indicated treatments
for 24 h. Data (n = 4) are represented as percent vs. vehicle-treated cells,
set as 100%, and graph bars represent SEM. One-way ANOVA with Tukey’s
post hoc test. **P < 0.01 vs. vehicle-treated cells.
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anti-CB2R antibody (101550; Cayman Chemical) directly linked to a plus PLA
probe, and a rabbit anti-HER2 antibody (C-18; Santa Cruz Biotechnology) di-
rectly linked to a minus PLA probe. For detection of other HER2 heteromers,
cells were incubated with a mixture of equal amounts of a mouse anti-HER2
antibody (44E7; Cell Signaling Technology) and rabbit anti-HER1 antibody (06-
847; EMD Millipore) for HER2–HER1 detection, or with a rabbit anti-HER3
antibody (1B2E; Cell Signaling Technology) for HER2–HER3 detection. A plus
anti-rabbit PLA probe and a minus anti-mouse PLA probe were used. For
negative controls, one of the primary antibodies was omitted. Ligation and
amplification were done with In Situ Detection Reagent Red (Sigma-Aldrich),
and slices were mounted in DAPI-containing mounting medium. Samples
were analyzed with a Leica SP2 confocal microscope (Leica Microsystems) and
processed with ImageJ software. Heteromer expression was calculated as the
number of red fluorescent spots (indicating that receptors are within suffi-
cient proximity)/total cells in the field. Representative images for each con-
dition were prepared for figure presentation by applying brightness and
contrast adjustments uniformly using Adobe Photoshop CS5.
Fusion Proteins for BRET and BiFC Assays. Sequences encoding amino acid
residues 1 to 155 and 156 to 238 of YFP Venus proteinwere subcloned into the
pcDNA3.1 vector to obtain YFP Venus hemitruncated proteins. The human
cDNAs for HER2, cannabinoid (CB2R), dopamine (D44R), and Ghrelin (GHS-
R1a) receptors, cloned into pcDNA3.1, were amplified without their stop
codons using sense and antisense primers harboring EcoRI and BamHI sites
to clone CB2R and GHS-R1a; XhoI and EcoRI to clone D44R; or NheI and XhoI
to clone HER2. The amplified fragments were subcloned to be in-frame with
restriction sites of pRLuc-N1 (PerkinElmer) or pEYFP-N1 (enhanced yellow
variant of GFP; Clontech) vectors, to generate plasmids that express proteins
fused to Rluc or YFP on the C-terminal end (HER2-Rluc, D44R-Rluc, HER2-YFP,
CB2R-YFP, or GHS-R1a-YFP). For BiFC experiments, the cDNA for HER2, CB2R,
and D44R were also subcloned into pcDNA3.1-nVenus or pcDNA3.1-cVenus
to generate a plasmid that expresses the receptor fused to the hemi-
truncated nYFP Venus or hemitruncated cYFP Venus on the C-terminal end
of the receptor (HER2-nVenus, D44-nVenus, or CB2R-cVenus).
CB2R Transmembrane Mutants. A pCDNA3-HA-CB2R plasmid was used as
template for the generation of seven mutants containing an HA tag, fol-
lowed by the N-terminal domain, one transmembrane domain, and the C-
terminal domain of CB2R. To assure the correct orientation of the resulting
peptides, in constructs containing even-numbered transmembrane domains,
the sequences corresponding to the transmembrane domains were reversed.
The primers used to generate these constructs are shown in SI Appendix,
Table S2.
HIV TAT-TM Peptides. Peptides containing the amino acid sequence of CB2R
and D4R transmembrane domains 5 were used as heteromer-disrupting agents.
To allow intracellular delivery and the correct membrane orientation, they
were fused (at the C-terminal domain) to the cell-penetrating HIV TAT pep-
tide. Their resulting TAT-TM peptides were TM5-TAT CB2R: DYLLSWLLFIAFL-
FSGIIYTYGHVLWYGRKKRRQRRR and TM5-TAT D4R: YVVYSSVCSFFLPCPLM-
LLLYWATFYGRKKRRQRRR.
They were synthetized at the Peptide Synthesis Facility at University
Pompeu Fabra.
Bioluminescence Resonance Energy Transfer Assays. HEK293 cells were tran-
siently cotransfected with a constant amount of a cDNA encoding HER2 or
D44R fused to Rluc protein (HER2-Rluc, D44R-Rluc) as BRET donor, and with
increasing amounts of a cDNA of the other receptor fused to YFP (CB2R-YFP,
HER2-YFP, GHS-R1a-YFP) as BRET acceptor. For quantification of protein-YFP
expression, fluorescence at 530 nm was analyzed in a FLUOstar Optima
fluorimeter (BMG Labtech). Fluorescence of cells expressing the BRET donor
only was subtracted from these measurements. BRET signal was analyzed
1 min after addition of the bioluminescent substrate coelenterazine H (5 μM;
Molecular Probes) with a Mithras LB 940 (Labnet Biotecnica). To quantify
protein-Rluc expression, luminescence was determined 10 min after addition
of 5 μM coelenterazine H. The net BRET is defined as [(long-wavelength
emission)/(short-wavelength emission)] − Cf, where Cf corresponds to [(long-
wavelength emission)/(short-wavelength emission)] for the Rluc construct
expressed alone in the same experiment. BRET is expressed as milli-BRET units
(mBU; net BRET × 1,000). In BRET curves, BRET was expressed as a function of
the ratio between fluorescence and luminescence × 100 (YFP/Rluc). To calcu-
late maximum BRET (BRETmax) from saturation curves, data were fitted using a
nonlinear regression equation and assuming a single phase with GraphPad
Prism software.
Bimolecular Fluorescence Complementation Assays. HEK293 cells cotrans-
fected with HER2 fused to the YFP Venus N terminus (nYFP) and CB2R fused to
the YFP Venus C terminus (cYFP) were treated with vehicle, the CB2R mu-
tants, or the indicated TAT-TM peptides (4 μM) for 4 h at 37 °C. Fluorescence at
530 nm (which only appears after YFP complementation due to proximity of
the two receptors fused to cYFP and nYFP hemiproteins) was quantified in a
FLUOstar Optima fluorimeter (BMG Labtech). Protein fluorescence expression
was determined as the fluorescence of the sample minus fluorescence of
nontransfected cells. Cells expressing HER2-nYFP and nYFP or CB2R-cYFP and
cYFP showed similar fluorescence levels to nontransfected cells.
Antibody-Capture [35S]GTPγS Scintillation Proximity Assays. Specific activation
of different subtypes of Gα proteins by THC (5 μM) was determined as pre-
viously described (46). Briefly, cell-membrane homogenates from the four
different cell lines [HEK293 cells transiently overexpressing HER2, CB2R, both
receptors (HER2–CB2R) simultaneously, or the corresponding empty vector
(pcDNA3)] were incubated in 96-well Isoplates (PerkinElmer Life Sciences) in
incubation buffer containing 0.4 nM [35S]GTPγS (PerkinElmer) and 50 or
100 μM GDP for Gi2, Gq/11, and Go, or for Gi1,Gi3, Gz, Gs, and G12/13 proteins,
respectively. Specific antibodies for each Gα subunit (mouse monoclonal anti-
Gαi1 and anti-Gαo, and rabbit polyclonal anti-Gαi2, anti-Gαi3, anti-Gαz, anti-Gαq/
11, anti-Gαs, and anti-Gα12/13; Santa Cruz Biotechnologies) and PVT scintillation
proximity assay beads coated with protein A (PerkinElmer) were used. Radio-
activity was quantified on a MicroBeta TriLux scintillation counter (PerkinElmer).
Animals and Treatments. All procedures involving animals were performed
with the approval of the Complutense University Animal Experimentation
Committee andMadrid Regional Government, according to European official
regulations. For the generation of orthotopic tumors, 5 × 106 HCC1954 cells
were injected into the fourth right mammary fat pad of anesthetized (with
4% isoflurane) 6-wk-old SCID female mice (Envigo). Tumor volume was
routinely measured with an external caliper, and when it reached an aver-
age volume of 200 mm3, animals were randomly assigned to the different
experimental groups: THC (1.5 mg·animal−1·dose−1) or sesame oil as vehicle.
Treatments were administered orally by gavage in 100 μL, three times a
week for 1 mo. At the end of the treatment, animals were killed and tumors
and organs were collected. Tumors were divided into portions for prepa-
ration of tissue sections for PLA staining (frozen in Tissue-Tek) and protein
extraction (snap-frozen), and were stored at −80 °C until analysis. For PLA
experiments, tumor samples were fixed by immersion in 4% para-
formaldehyde solution for 24 h at 4 °C, washed in PBS, and cryopreserved in
a 30% sucrose solution at 4 °C. Before sectioning, tumors were frozen in
Tissue-Tek, and 20-μm-thick slices were cut on a freezing cryostat (Leica Jung
CM-3000) and mounted on glass slides.
Patient-Derived Xenografts. Human breast tumors used to establish PDXs
were from biopsies or surgical resections at Vall d’Hebron University Hospital,
and were obtained following the institutional guidelines and approval of
Fig. 8. Schematic drawing of the proposed mechanism of control of
HER2 activity by CB2R. (A) HER2 forms heteromers with CB2R at the plasma
membrane of HER2+ breast cancer cells, protecting it from degradation and
favoring its prooncogenic signaling. (B) Disruption of HER2–CB2R hetero-
mers, either by THC or by specific tools targeting CB2R transmembrane do-
main 5, triggers inactivation of HER2 by inducing the separation of HER2–
HER2 homodimers and increasing HER2 susceptibility to degradation by the
E3 ligase c-CBL. HER2 degradation and CB2R activation result in antitumor
responses.
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the institutional review boards at Vall d’Hebron University Hospital in ac-
cordance with the Declaration of Helsinki. Written informed consent was
obtained from all patients who provided tissue. Fragments of patient samples
were implanted into the mammary fat pad of NOD CB17-Prkdcscid (NOD/
SCID) (SM-NOD-5S-F; Janvier) and maintained with 17β-estradiol (1 μM)
(E8875-1G; Sigma) in the drinking water. Mice were maintained and treated
in accordance with the institutional guidelines of the Vall d’Hebron University
Hospital Care and Use Committee.
Tissue Microarrays. Two different tumor series, in a TMA format, were used in
this study. TMA 1 consisted of 57 samples corresponding to newly diagnosed
HER2+ breast cancer patients operated at 12 de Octubre University Hospital
between 1999 and 2013, and prior to any treatment. TMA 2 was previously
described in ref. 47, and contained 138 high-grade ductal breast cancer
samples obtained before treatment at the Vall d’Hebron University Hospital,
Virgen del Rocío Hospital (Seville, Spain), and MD Anderson Cancer Center
(Madrid, Spain) between 2003 and 2014. Of them, 39 corresponded to
HER2+ cases. In both cases, paraformaldehyde-fixed and paraffin-embedded
blocks of tumor tissue were used to generate the corresponding TMAs by
punching two 1-mm spots of each patient’s biopsy.
Statistics. Kaplan–Meier survival curves were statistically compared by the
log-rank test. The best cutoff was manually selected for each TMA. In TMA 1,
the PLA signal ranged from 1.3 to 16.0, and the cutoff was set at 8.0. In TMA
2, the PLA signal ranged from 1.5 to 6.0, and the cutoff was set at 4.0.
Unpaired, independent groups of two were analyzed by two-tailed Stu-
dent’s t test. When multigroup comparison was required, data were ana-
lyzed by one-way ANOVA with Tukey’s post hoc test. Tumor growth curves
from vehicle- and THC-treated animals were statistically compared by two-
way ANOVA. Significance level was below 0.05 in all cases. Results are shown
as mean ± SEM, and the number of experiments is indicated in every case.
All analyses were carried out using GraphPad software.
Data supporting the findings of this study are available within the paper
and SI Appendix.
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